The FDA has permitted the marketing of IDx-DR, the first artificial intelligence medical device to detect more than a mild level of diabetic retinopathy in adults with diabetes, according to a press release.
IDx-DR (IDx LLC), a software program that uses an artificial intelligence algorithm to analyze images of the eye taken with the Topcon NW400 retinal camera, is the first device authorized for marketing that provides a screening decision without a clinician having to interpret results, the release said.
It provides doctors with two results, either positive for more than mild diabetic
Uncategorized